
ParcelBio
Advancing next-generation mRNA medicines.
About
ParcelBio is developing transformative mRNA medicines using its proprietary APEXm™ platform, engineered for significantly higher potency and durability than existing mRNA technologies. This platform enables a new class of therapies, including in vivo CAR-T for autoimmune diseases and oncology, and durable delivery of therapeutic proteins. ParcelBio serves patients by creating advanced mRNA medicines that can reach therapeutic thresholds previously unattainable.
Listed competitors
Show 6 more similar companies
Also in this space
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Genomics
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Artificial Intelligence
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to ParcelBio?
People comparing tools land here. Get listed beside these.
Copy ParcelBio's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Tech stack
Detected on parcelbio.com, last scanned 17 Nov 2026. Run your own scan
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Benchmarking
See how your site ranks against 16,849 startups
ParcelBio sits in the 25th percentile for Domain Rating. Check where yours lands, free.
ParcelBio has a Domain Rating of 18, the 25th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Below median
Scan yoursSite Speed
Above median
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
ParcelBio scores 39. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when ParcelBio changes
Used ParcelBio? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Are there companies like ParcelBio?
Yes. We list 8 companies like ParcelBio, including Moderna, BioNTech and Degron Therapeutics.
Is ParcelBio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for ParcelBio is 65 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has ParcelBio raised?
ParcelBio has raised a total of $100M in funding. The most recent round on record is Series A.
How many employees does ParcelBio have?
ParcelBio has approximately 6 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for ParcelBio:
Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch ParcelBio and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini


